Congress
$15,001–$50,000
Traded Nov 20, 2025 · disclosed 29 days laterSits on House Energy and Commerce
7 different filers disclosed JNJ within 90 days.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Nov 26, 2025 · Filed Dec 1, 2025
A Johnson & Johnson director paid $258K out of pocket for Johnson & Johnson shares. Shares held went up 209% with this purchase.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$257,688
Shares × reported transaction price
$100K–$500K
+208.9%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
Not enough history to judge
Confirmed open-market purchases by the same insider in the available history
No other insider purchases within 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
43 days after results of Oct 14, 2025, 56 days before results of Jan 21, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $207.56 on Nov 26, 2025, at its 52-week high, after a 9% rise over the previous 30 trading days
52-week range $142.06 (Jan 10, 2025) to $207.56 (Nov 26, 2025), 100% of the way up, from 250 adjusted closes. 30 trading days earlier: $191.17 on Oct 15, 2025. Describes the past only, not a forecast
RSI 83, 23% above its 200-day average, 9% above its 50-day average, at the 52-week high, 20-day volatility 14% a year, against the S&P 500: +12 points over 1 month, +14 points over 3 months, +20 points over 6 months
From the adjusted closes up to Nov 26, 2025. RSI: Wilder's 14-day relative strength index (0 to 100). Averages: the last 50 and 200 closes. Volatility: standard deviation of the last 20 daily returns, annualised. S&P 500: the stock's move minus SPY's between the same dates (21, 63 and 126 trading days). Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
John G Morikis's first open-market purchase of JNJ in filings since 2006
Compared with every open-market purchase and sale of this company in SEC filings since 2006. A fact about the record, not a signal to trade
FDA approved Darzalex Faspro on Nov 19, 2025, 7 days before this trade.
New use approved (efficacy supplement). Active ingredient: Daratumumab and Hyaluronidase-Fihj. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −2.7% | +0.2% | −2.9% |
| 30 days | +0.9% | +0.2% | +0.7% |
| 90 days | +21.0% | +0.7% | +20.3% |
| 180 days | +8.8% | +11.3% | −2.5% |
Past results only. Not a forecast.
Congress
Traded Nov 20, 2025 · disclosed 29 days laterSits on House Energy and Commerce
7 different filers disclosed JNJ within 90 days.
Fund moves
87 tracked managers disclosed the same change for Q3 2025. From a 13F filed Dec 18, 2025 covering holdings at Sep 30, 2025 — a quarter-end snapshot, not a live trade.
Insider filing
Traded Dec 9, 2025 · filed 2 days later
Compensation award — excluded from discretionary-purchase analysis.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.